Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20862666 | 0.69 | JAK3 (0.55) | JAK3LRRK2NPC1RAB9AMAPT | |
| SCHEMBL20862642 | 0.69 | JAK3 (0.55) | JAK3LRRK2NPC1RAB9AMAPT | |
| SCHEMBL20862485 | 0.69 | JAK3 (1.00) | JAK3LRRK2 | |
| SCHEMBL3954391 | 0.69 | JAK3 (1.00) | JAK3LRRK2 | |
| SCHEMBL18967632 | 0.68 | KHK (0.71) | JAK3LRRK2 | |
| SCHEMBL27366298 | 0.68 | JAK3 (0.50) | JAK3LRRK2NPC1RAB9AMAPT | |
| SCHEMBL27741347 | 0.67 | HTT (0.42) | JAK3LRRK2NPC1MAPTTP53 | |
| SCHEMBL19725048 | 0.67 | JAK3 (0.51) | JAK3LRRK2NPC1RAB9AMAPT | |
| SCHEMBL19826894 | 0.66 | LRRK2 (0.53) | JAK3LRRK2NPC1RAB9AMAPT | |
| SCHEMBL24371998 | 0.66 | ADRA1A (0.52) | JAK3LRRK2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174511-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174511-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | JAK3 14/4885LRRK2 440/4885NPC1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.